TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
119.81
+0.66 (0.55%)
At close: Sep 17, 2025, 4:00 PM EDT
120.95
+1.14 (0.95%)
Pre-market: Sep 18, 2025, 9:09 AM EDT
TransMedics Group Revenue
TransMedics Group had revenue of $157.37M in the quarter ending June 30, 2025, with 37.68% growth. This brings the company's revenue in the last twelve months to $531.29M, up 48.09% year-over-year. In the year 2024, TransMedics Group had annual revenue of $441.54M with 82.74% growth.
Revenue (ttm)
$531.29M
Revenue Growth
+48.09%
P/S Ratio
7.59
Revenue / Employee
$729,797
Employees
728
Market Cap
4.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 30, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TMDX News
- 1 day ago - TransMedics: Upcoming Trials Are Critical - Seeking Alpha
- 9 days ago - TransMedics Group, Inc. (TMDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - TransMedics: Just Like The CEO, I'm Buying - Seeking Alpha
- 23 days ago - TransMedics to Present at Upcoming September Investor Conferences - PRNewsWire
- 24 days ago - TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3 - Seeking Alpha
- 6 weeks ago - TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial - PRNewsWire
- 6 weeks ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - TransMedics: Continued Strength Suggests Further Upside - Seeking Alpha